Clinical and economic outcomes of involving pharmacists in the direct care of critically ill patients with infections*
- 1 December 2008
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Critical Care Medicine
- Vol. 36 (12), 3184-3189
- https://doi.org/10.1097/ccm.0b013e31818f2269
Abstract
To determine whether the absence or presence of clinical pharmacists in intensive care units (ICUs) results in differences in mortality rates, length of ICU stay, and ICU charges for Medicare patients with nosocomial-acquired infections, community-acquired infections, and sepsis. The type and level of pharmacy services provided to ICUs were obtained from a 2004 national survey. Clinical pharmacy services were defined as having at least a partial pharmacist full-time equivalent specifically devoted to the ICU for the purpose of direct involvement in patient care. Infections were defined using International Classification of Diseases, Ninth Revision, Clinical Modification codes. ICU outcome data were drawn from the 2004 modified Medicare provider analysis and review. Depending on the infection studied, the involvement of clinical pharmacists was evaluated in 8,927–54,042 patients from 265 to 276 hospitals. None. Mortality rates, length of ICU stay, Medicare charges, drug charges, and laboratory charges for each of the infections categorized according to the absence or presence of clinical pharmacists. Compared to ICUs with clinical pharmacists, mortality rates in ICUs that did not have clinical pharmacists were higher by 23.6% (p < 0.001, 386 extra deaths), 16.2% (p = 0.008, 74 extra deaths), and 4.8% (p = 0.008, 211 extra deaths) for nosocomial-acquired infections, community-acquired infections, and sepsis, respectively. Similarly, ICU length of stay was longer by 7.9% (p < 0.001, 14,248 extra days), 5.9% (p = 0.03, 2855 extra days), and 8.1% (p < 0.001, 19,215 extra days) for nosocomial-acquired infections, community-acquired infections, and sepsis, respectively. ICUs that did not have clinical pharmacists had greater total Medicare billings of 12% (p < 0.001, $132,978,807 extra billing charges), 11.9% (p < 0.001, $32,240,378 extra billing charges), and 12.9% (p < 0.001, $224,694,784 extra billing charges) for nosocomial-acquired infections, community-acquired infections, and sepsis, respectively. Similar findings were observed for Medicare drug charges and laboratory charges. The involvement of clinical pharmacists in the care of critically ill Medicare patients with infections is associated with improved clinical and economic outcomes. Hospitals should consider employing clinical ICU pharmacists.Keywords
This publication has 21 references indexed in Scilit:
- Cost implications of and potential adverse events prevented by interventions of a critical care pharmacistAmerican Journal of Health-System Pharmacy, 2007
- Clinical and economic outcomes of pharmacist-managed antimicrobial prophylaxis in surgical patientsAmerican Journal of Health-System Pharmacy, 2007
- Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in AdultsClinical Infectious Diseases, 2007
- Clinical and economic outcomes of pharmaceutical services related to antibiotic use: a literature reviewInternational Journal of Clinical Pharmacy, 2007
- The critical care clinical pharmacist: Evolution of an essential team memberCritical Care Medicine, 2006
- Clinical and economic outcomes of pharmacist-managed aminoglycoside or vancomycin therapyAmerican Journal of Health-System Pharmacy, 2005
- Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated PneumoniaAmerican Journal of Respiratory and Critical Care Medicine, 2005
- Guidelines on critical care services and personnel: Recommendations based on a system of categorization of three levels of care*Critical Care Medicine, 2003
- Position paper on critical care pharmacy servicesCritical Care Medicine, 2000
- Impact of a clinical pharmacist in a multidisciplinary intensive care unitCritical Care Medicine, 1994